[1] World Health Organization. 2018. Global tuberculosis report. Geneva, Switzerland.
[2] Dowdy DW, Chaisson RE, Moulton LH, et al. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS, 2006; 20, 751−62. doi:  10.1097/01.aids.0000216376.07185.cc
[3] World Health Organization. Policy statement: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. 2011.
[4] Dorman SE, Schumacher SG, Alland D, et al. Xpert MTB/RIF Ultra for detection of Mycobacterium tuberculosis and rifampicin resistance: a prospective multicentre diagnostic accuracy study. Lancet Infect Dis, 2018; 18, 76−84. doi:  10.1016/S1473-3099(17)30691-6
[5] Bahr NC, Nuwagira E, Evans EE, et al. Diagnostic accuracy of Xpert MTB/RIF Ultra for tuberculous meningitis in HIV-infected adults: a prospective cohort study. Lancet Infect Dis, 2018; 18, 68−75. doi:  10.1016/S1473-3099(17)30474-7
[6] Rindi L, Ali G, Fabiani B, et al. Detection of Mycobacterium tuberculosis from paraffin-embedded tissues by GeneXpert MTB/RIF. Tuberculosis, 2017; 106, 53−5. doi:  10.1016/j.tube.2017.06.005
[7] Cave MD, Eisenach KD, McDermott PF, et al. IS6110: conservation of sequence in the Mycobacterium tuberculosis complex and its utilization in DNA fingerprinting. Mol Cell Probes, 1991; 5, 73−80. doi:  10.1016/0890-8508(91)90040-Q
[8] World Health Organization. WHO meeting report of a technical expert consultation: Non-inferiority analysis of Xpert MTB/RIF Ultra compared to Xpert MTB/RIF. 2017.
[9] Ramaswamy S, Musser JM. Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis. Tubercle Lung Dis, 1998; 79, 23−9.
[10] Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol, 2011; 6, 1067−82. doi:  10.2217/fmb.11.84